The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal2000+abdulrahman alfozan500+pope francis500+olise500+delaware vs middle tennessee prediction500+bayern de múnich200+gme1000+flashscore200+

Category:All Headlines World & Geopolitics Markets & Economy Tech & AI PoliticsSearch results for: "Eli Lilly Releases Open L" (30 stories)

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12

Lead StoryEli Lillyworld

Mar 12

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPc0dRYmJRZDd5eE1rVkNFTS0zY0NRdHZ4Wm5YaDNhZHo2ZXBwVzlXR2E1ZGxnR2o0dTc3QksxWGpVMjVtMlZxajJGXy04ZERxRmxLVHVKOW15UjR6WnpubHJzVTdYUWVvOFBoYzFpVWFiYWtHZHNwVlVRczNrMFBIRVYxS203THVjT2VsRjFsLVNtMTJiNmRHUHdMeUo3SkJDbWdULVJIM2JQWXNBMU4xWGtkMGk0Mi1wVElKRzVn?oc=5" target="_blank">An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12</a>&nbsp;&nbsp;Eli Lilly

Read Full Story Related Trends

Google Trends & Trending Search Intelligence

Real-time search volume

2000+22m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories

500+32m ago

abdulrahman alfozan

OpenAI engineer arrested in bugging of executive conference room

Filter stories

500+32m ago

pope francis

The Myth of St. Francis

Filter stories

500+32m ago

olise

Bayern’s Michael Olise sent off for 2 yellow cards within seconds in Champions League

Filter stories

Search Results for "Eli Lilly Releases Open L"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed

U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes

Eli Lillygeneral

Sep 24

U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNV3FNMlhIRnBEdEdrd013dEVDZU53S21XSzZCR2RyM3A1S2M2c19pSDVpdnUxbzJjUFVuYTFodGlHNDdNeTlmdzVmOVVqTGlFZjIxR2pqaGFwLTJNLTFPYXhyc1d3dFFmTmZxcnBaQzl4ZG9ROHYxQWRBTHM5R1ZqMWtaQ1dRNWl1UXM3d1JsRUFCdFBkMVJWTVFqV1VlZ2hVcWhlS2k3Y3lmX2cyc0M5YWxCS1FTcHNkeWF6RGNZTQ?oc=5" target="_blank">U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes</a>&nbsp;&nbsp;Eli Lilly

World News, Markets & Google Trends

Top Headline Story

An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12

Google Trends & Trending Search Intelligence

lamine yamal

abdulrahman alfozan

pope francis

olise

Search Results for "Eli Lilly Releases Open L"

U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes

Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

Lilly announces three acquisitions to build infectious disease portfolio

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI

Lilly Expands Retatrutide Access Amid Doctor Pushback

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

Lilly announces plans to open Lilly Gateway Labs site in Philadelphia

Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

An Open Letter From Eli Lilly and Company Regarding Certain Practices Related to Mounjaro® and Zepbound

Lilly Warns Patients About Counterfeit and Compounded Medicines Releases Open Letter and Takes Further Legal Action Against Counterfeit, Fake, Unsafe, and Untested Products

Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2